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Abstract
Background: Achromobacter xylosoxidans (AX) is known for intrinsic resistance to disinfectants. Our laboratory
routine surveillance system detected an unexpected rise in AX bloodstream infections in a 2200-bed hospital.
An epidemiological investigation was conducted to find the source and disrupt further transmission.
Methods: Outbreak cases were defined as patients with at least one positive blood culture positive for AX from
May 2014 to May 2015. Medical records were reviewed, affected wards, as well as the microbiology laboratory
were audited. Additionally, microbiologic culture and biofilm staining for suspected antiseptic reusable tissue
dispensers were performed, and isolated AX strains were typed using RAPD PCR and PFGE.
Results: During the outbreak period, AX were isolated from blood cultures from 26 patients. The retrospective cohort
study did not reveal common risk factors. The clinical features of the case patients suggested a pseudobacteremia.
The reusable tissue dispensers containing Incidin® Plus solution product were found to be contaminated with
biofilm-forming AX. Typing of the isolates revealed that blood culture isolates were identical with the strains
found in the dispensers.
Conclusions: After changing the usage of the product to single-use and educating staff, the outbreak was
terminated. Contamination of dispensers occurred due to insufficient reprocessing, since biofilm disrupting
steps were not included in the process.
Keywords: Healthcare-associated infections, Infection control, Biofilm, Environmental cleaning, Disinfection,
Tissue dispensers, Achromobacter xylosoxidans
Background
Achromobacter xylosoxidans (AX) is a well-known patho-
gen in cystic fibrosis patients but it is rarely seen in other
patients [1]. It is, however, widely distributed in nature
and its ability to produce biofilm contributes to its high
tenacity and survival under unfavourable conditions [2].
Even antiseptics and disinfectants are not always able to
eliminate Achromobacter spp. [3]. In January 2015 we
experienced a significant increase of AX bloodstream
infections (BSI) on one of our medical intensive care units
(ICU) in our 2,200-bed hospital, and such infections had
been rarely seen in the past (AX isolates in 2012: 3 BSI, 4
in respiratory materials, 4 in wound swabs; in 2013: 0 BSI,
2 in respiratory materials, 8 in wound swabs). We also
detected an increase in AX isolations from materials
other than blood cultures (respiratory materials, rectal
and wound swabs). We immediately started investigat-




Heidelberg University Hospital (HUH) is a 2,200-bed
university teaching hospital and one of the largest and
most renowned hospitals in Germany. It provides a full
range of medical and surgical services, including active
* Correspondence: nico.mutters@med.uni-heidelberg.de
1Department of Infectious Diseases, Heidelberg University Hospital, Im
Neuenheimer Feld 324, D-69120 Heidelberg, Germany
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Günther et al. BMC Infectious Diseases  (2016) 16:584 
DOI 10.1186/s12879-016-1909-0
programs for solid organ, and bone marrow transplan-
tation. Outbreak cases were defined as patients with at
least one positive blood culture positive for AX from
May 2014 to May 2015. This rather general definition
of outbreak cases was used to increase sensitivity that
no possible outbreak case would be missed.
Tissue dispensers
The tissue dispenser buckets (CELTEX®-wipes; Loftex,
Bremen, Germany) contain tissues with Incidin® Plus
(Ecolab, Monheim, Germany), a Glucoprotamin based
disinfectant (Fig. 2a). They have an intended service
time of 28 days. After that they need to be reprocessed
and refilled with new tissues. According to the manu-
facturer’s recommendations, multi-use after reproces-
sing is allowed. However, single-use is recommended
for areas with high infection risk (ICU, hemato-
oncology, neonatology, burn units). Reprocessing needs
to include 3 steps. 1) Product residues and remaining
tissues need to be thrown away and dispenser buckets
need to be allowed to dry. 2) Rinse with hot water
(>55 °C), let dry again 3) wipe-down disinfection with
an alcohol-based disinfectant (provided in form of a
wipe by the manufacturer) and let dry again. After
completion of this 3-step processing dispensers can be
refilled with tissues and used for another 28 days, thus
multi-use is allowed.
Isolation and identification of A. xylosoxidans isolates
Isolates were recovered from blood samples incubated in
the BACTEC™ FX automated microbial detection system
(BD diagnostics, Sparks, USA). After Gram staining,
isolates were inoculated on appropriate media and incu-
bated at 37 °C overnight. Isolates recovered from other
materials were also inoculated on appropriate media and
incubated at 37 °C overnight. Identification of bacteria
was done by matrix-assisted laser desorption ionization
time-of-flight mass spectrometry as described elsewhere
[4]. Susceptibility testing was performed according to
EUCAST criteria using the Vitek2 system (bioMérieux
Clinical Diagnostics, Marcy l'Etoile, France).
Epidemiologic investigation
After an increased incidence of cases with a blood
culture positive for AX was identified by the microbio-
logical laboratory, an epidemiological investigation was
immediately started by the infection control team in the
end of January/beginning of February 2015 (① in Fig. 1).
A retrospective cohort study to identify common risk
factors for AX BSI was conducted. Furthermore, review
of all microbiological records to identify undetected
cases retrospectively and to determine the baseline BSI
rate of AX prior to the suspected outbreak was per-
formed. The patients’ medical records of the additional
identified cases were also reviewed to identify common
Fig. 1 Outbreak chart. AX detected in blood cultures or central venous catheters BSI (grey), AX detected elsewhere (black) and interventions (arrows)
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risk factors. The microbiological laboratory was audited
to exclude possible contamination of the blood cultures
in the laboratory. The identified wards with the majority
of the cases were visited and blood culture sampling
practices were reviewed. Additionally, the antiseptics
and disinfectants used within these wards were checked
regarding the sort of products, disinfectant agents, usage
patterns of the different wards and possible recent
changes of products.
Microbiological investigation of the reusable surface
disinfection tissue dispensers
Upon completion of the epidemiological investigations,
the microbiological and molecular investigation followed
in February 2015 (② in Fig. 1), including observations of
the processing practices of the tissue dispensers. Disin-
fectant samples were collected from 26 dispensers
localized in patient rooms or central service areas.
Additionally, two samples were collected from statio-
nary metering units for disinfectants used for refilling
the tissue dispensers. Tissues were only tested from
dispensers that were found contaminated.
Each sample was tested for bacterial contamination by
membrane filtration of 50 ml disinfectant solution
trough a 0.45 μm nitrocellulose membrane (Sartorius
Stedim, Göttingen, Germany) and rinsed with 250 ml of
sodium peptone solution (Merck Millipore, Darmstadt,
Germany). Subsequently, the filter was transferred on a
Caso-Agar containing LTHTh as neutralizer (Merck
Millipore, Darmstadt, Germany). The neutralizer was
validated for effectively neutralizing the tested disinfectant
agents prior to this study (data not shown). The media
were incubated for 5 days at 37 °C and checked for mi-
crobial growth every 24 h. Colony forming units (CFU)
were counted. If growth was detected, bacteria were
identified by MALDI-TOF mass spectrometry (Bruker
Daltonik, Bremen, Germany).
Molecular investigation
All AX isolates were typed using random amplified
polymorphic DNA PCR (RAPD PCR) and pulsed field
gel electrophoresis (PFGE) (② in Fig. 1). RAPD PCR was
performed using primer 272 as described elsewhere [5].
Typing by PFGE of each detected Achromobacter isolate
was performed using DraI as restriction enzyme. Ana-
lysis of the gained typing results was performed according
to the criteria defined by Tenover et al. [6].
Analysis of biofilm formation in the contaminated tissue
dispensers
To analyze the bacterial habitats in the disposal tissue
dispensers, dispensers were collected and possible bio-
film formation was tested. Tissue dispenser buckets were
screened for bacterial biofilms using a 0.1 % crystalviolet
staining solution (Sigma Aldrich, Taufkirchen, Germany).
The collected tissue samples were fixed in buffered
formalin, embedded in paraffin and subsequently sliced
into 4 μm paraffin sections. After deparaffinization with
xylene and rehydration in graded alcohols, acridine orange
staining (Becton Dickinson, Heidelberg, Germany) was
performed to detect biofilms and/or adherent bacteria
on singular tissue fibers.
Results
Epidemiological investigation
After the routine surveillance system of our laboratory
had detected 13 cases of AX BSIs in January and begin-
ning of February 2015 as well as an additional increase
in AX isolations from other materials, the epidemio-
logical investigation was started concurrently (① in
Fig. 1). Initially, injection of drugs or incorrect handling
of intravascular catheters was suspected to cause the
BSIs. The performed cohort study, however, did not find
any common risk factor to identify the source. When
traced back to the wards, most of the cases were found
on two connected internal medicine wards: an intensive
care unit (ICU) and an intermediate care unit (IMC).
Patients are usually transferred from the ICU to the
IMC when they clinically improve. Further sporadic
cases across the hospital could also be observed, how-
ever, no spatial or epidemiological connection between
them could be identified. In total, we identified 26
patients from December 2014 to February 2015 with at
least one episode of AX bacteraemia; 4 patients had
multiple positive blood cultures (Fig. 1). Most of the
cases were clinically asymptomatic and did not show
symptoms of an infection with AX.
Retrospectively, from 1st May 2014 to 1st May 2015,
49 AX isolates were detected in different clinical speci-
men of 28 patients of the same clinical unit. Of those, 19
patients were identified with at least one episode of AX
bacteraemia, and three patients with multiple blood cul-
tures positive for AX (Fig. 1). The clinical characteristics
retrieved from medical records suggested a contamination
rather than actual infection with AX.
The audit of the microbiological laboratory revealed
that a contamination in the laboratory was very unlikely
especially since the spatial distribution of the cases
pointed to the medical ICUs. While common risk factors
i.e. intravascular catheterization and invasive procedures
were often found in all ICU patients, regardless of med-
ical or surgical patients, curiously AX BSI episodes
mainly occurred on medical ICUs while the surgical
ICUs only had sporadic and very few cases. Since blood
culture sampling methods and handling of intravascular
catheters did not differ between the surgical and medical
department, we suspected a difference in antiseptic use
between the departments. While the same surface
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disinfection and hand disinfection products were used in
both departments, only the medical department used
reusable surface disinfection tissue dispensers. Those
tissues contained Incidin® Plus (Ecolab, Monheim,
Germany), a Glucoprotamin based disinfectant used for
disinfection of patient-related areas i.e. nightstands and
bedrails. Additionally, they were used by the healthcare
workers responsible for blood sampling to disinfect the
trays where all materials necessary for blood sampling
i.e. collection tubes, needles and blood culture bottles
were placed on. The reusable tissue dispensers were
manually processed supposedly according to manufac-
turer’s recommendations of every 28 days. However,
compliance with and efficacy of manual processing in
clinical practice was never assessed. Thus, we started a
microbiological investigation of the reusable dispensers
and the actual manual processing that was carried out.
Microbiological and molecular investigations
Incidin® Plus solutions from 23 dispensers were collected
and tested (② in Fig. 1). A contamination with AX of at
least ≥10^3 CFU per mL was found in 69.6 % (16/23) of
the tested dispensers. All tissues tested from contaminated
dispensers were also found contaminated with AX. The
tested stationary metering units for disinfectants showed
no contamination with AX. No other bacteria than AX
was detected.
The molecular typing investigations showed, that 7
AX isolates recovered from patients’ blood cultures were
indistinguishable from 15 typed AX isolates in the
dispensers and could therefore be regarded as part of
the cluster type A. One AX isolate showed minimal dif-
ferences in banding pattern of PFGE and was therefore
interpreted as closely related type A1. The typing results
showed congruent results for both typing techniques.
Two further isolates recovered from blood cultures col-
lected from patients of other clinical units showed differ-
ent banding patterns in both typing techniques compared
to the outbreak isolates and was assigned to type B.
Infection control interventions
Contaminated dispensers were removed from affected
wards starting from 2nd March 2015 (③ in Fig. 1).
Additionally, processing of dispensers was terminated
and usage of dispensers was only allowed as single use.
Measures were implemented until 17th March 2015 (④ in
Fig. 1). Within 2 months of follow up, no further episodes
of AX bacteraemia or detection of AX in clinical speci-
mens from the affected wards were identified (Fig. 1).
Analysis of biofilm formation in the contaminated tissue
dispensers
Bacterial biofilms were detected in all reprocessed tissue
dispensers within 1 week after completion of reprocessing.
Biofilms were detected on buckets (Fig. 2b) as well as on
tissues (Fig. 2d). Clearly visible bacterial contamination on
tissue fibers was detectable after 5 weeks (Fig. 2d) in
reprocessed tissue dispensers. In contrast, newly assem-
bled tissue dispensers that were never reprocessed did
not show biofilm formation (Fig. 2c).
Fig. 2 Pictures of dispensers and biofilm stains. a: a tissue dispenser bucket. b: AX biofilm on wall and bottom of dispenser buckets stained with
crystalviolet; black arrows: increased biofilm formation on former liquid levels (upper arrows) and at the bottom of the bucket (lower arrow).
c: acridine orange stained tissue sample of a newly assembled dispenser d: AX biofilm detected by acridine orange staining on tissues
collected from a dispenser 5 weeks after reprocessing (white arrows: biofilm; * tissue fiber; 200× magnification)
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Discussion and conclusions
The pseudobacteremia was caused by contaminated
Incidin® Plus tissues that were used to clean patient-
related areas and trays for blood sampling. The tissues
were also used to wipe off the blood culture bottles after
removal of the lid, leading to the contamination of
blood cultures and causing the pseudobacteremia. The
contamination of tissue dispensers was permitted by
breaches in the manual processing of the reusable tis-
sue dispensers. Our investigation revealed that during
tissue dispenser processing the same disinfectant was
used for cleaning the dispenser buckets as well as in
the tissues. Solutions with only one specific active
agent, however, may get contaminated and thereby
contribute to the transmission of pathogens [3]. Inves-
tigating the manual cleaning process of the tissue dis-
pensers at our hospital revealed that no high
temperature step or the use of a biofilm-active clean-
ing agent was used in the cleaning process. Without
those essential steps manual or automatic processes
must be considered insufficient for prevention of re-/
contamination of tissues [7]. The continuous use of
the same or similar disinfectant in processing reusable
dispensers supports the selection of resistant clonal
lineages, which can result in the establishment of resident
homogenous bacterial communities in such dispensers.
Bacteria in biofilms are then able to adapt to the used
disinfectant and survive the reprocessing procedure.
Consequently, extensive bacterial contamination of
environmental surfaces by standard disinfection proce-
dures is possible [8]. The dispensers contaminated with
biofilm-forming Gram-negatives, such as AX, can then
become a source of pathogen transmission and possible
consecutive infections [9, 10]. Infection control depart-
ments should be aware of reusable tissue dispensers
and evaluate the internally used processing procedures.
In areas where patients are at high-risk for developing
an infection (ICU, hemato-oncology, neonatology, burn
units, transplant units) tissue dispenser should strictly
be used according to manufacturers’ recommendations
and preferably as single-use only.
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